Chronic obstructive pulmonary disease, or COPD in short, covers a group of lung conditions including chronic bronchitis and emphysema (shortness of breath), all marked by chronic inflammation of the air passages. There are several types of approved medications for COPD, such as Bronchodilators, Corticosteroids, Methylxanthines, Roflumilast, Mucoactive drugs, and Antibiotics. COPD is the third leading cause of death worldwide, affecting more than 390 million people globally.
The stock we are bringing to your attention today is that of Verona Pharma (VRNA), developing a groundbreaking COPD drug with a novel mechanism, marking the first major innovation in COPD treatment in over a decade.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com